{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Metropolitan Desk", "lead_paragraph": "Jack Loviglio has little in common with Charles Cullen, the New Jersey nurse who prosecutors say has admitted killing 30 to 40 patients. But they share two traits, and that is enough to make Mr. Loviglio scream. Both are men, and both are nurses.", "headline": {"main": "Slaying Suspect Is a Stain on Profession, Male Nurses Say"}, "abstract": "Allegations that Charles Cullen, male nurse, killed 30 to 40 patients are further blow to men in nursing profession, whose lives are already burdened by overcautious hospital policies, edgy patients and gender-biased medical scrubs; male nurses say they are classified as either gay, medical school dropouts or predators; only 5.4 percent of 2.7 million registered nurses in US are men, but there have been number of high-profile cases of male nurses who kill; photo (M)", "print_page": "55", "word_count": 1029, "_id": "4fd234688eb7c8105d7c5474", "snippet": "Jack Loviglio has little in common with Charles Cullen, the New Jersey nurse who prosecutors say has admitted killing 30 to 40 patients. But they share two traits, and that is enough to make Mr. Loviglio scream.    Both are men, and both are nurses.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/12/21/nyregion/slaying-suspect-is-a-stain-on-profession-male-nurses-say.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "CULLEN, CHARLES"}, {"name": "subject", "value": "MEN"}, {"name": "subject", "value": "NURSING AND NURSES"}, {"name": "subject", "value": "DISCRIMINATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "SERIAL MURDERS"}, {"name": "subject", "value": "HOMOSEXUALITY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Patrick", "lastname": "HEALY"}], "original": "By PATRICK HEALY"}, "document_type": "article", "pub_date": "2003-12-21T00:00:00Z", "section_name": "Health; New York and Region"}, {"type_of_material": "News", "blog": [], "news_desk": "Week in Review Desk", "lead_paragraph": "A popular prescription drug to prevent unwanted pregnancies is safe enough that it should be made available over the counter to the women who urgently need it, an advisory committee to the Food and Drug Administration recommended last week. The F.D.A.'s commissioner, Mark McClellan, must now decide to accept or reject the finding, and faces an intense debate over the ethics of selling the morning-after pill, called Plan B, as if it were no different from aspirin, for example. But what about the scientific question? If the pill is so safe, and so important, why was it sold by prescription in the first place, as it has been since 1999?", "headline": {"main": "The Nation; There's a Blurry Line Between Rx and O.T.C."}, "abstract": "FDA decision-making on selling drugs by prescription or over-the-counter takes into account many factors that have nothing to do with science or patient safety, such as marketing and financial considerations, politics, doctors' concerns and consumer psychology; photo of late Sen Hubert Humphrey, onetime pharmacist who sponsored 1951 law authorizing FDA to classify drugs (M)", "print_page": "3", "word_count": 908, "_id": "4fd249138eb7c8105d7e6127", "snippet": "A popular prescription drug to prevent unwanted pregnancies is safe enough that it should be made available over the counter to the women who urgently need it, an advisory committee to the Food and Drug Administration recommended last week.     The...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/12/21/weekinreview/the-nation-there-s-a-blurry-line-between-rx-and-otc.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "HUMPHREY, HUBERT H JR"}, {"name": "glocations", "value": "UNITED STATES"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "MARKETING AND MERCHANDISING"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "CONSUMER PROTECTION"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "REGULATION AND DEREGULATION OF INDUSTRY"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2003-12-21T00:00:00Z", "section_name": "Health; Week in Review"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Kentucky's Medicaid program was $230 million in the red last year, and drastic cuts were on the table. A state panel proposed excluding Zyprexa, an antipsychotic medication that is the state's single biggest drug expense, from the Medicaid list of preferred medications. That was when the National Alliance for the Mentally Ill and the Kentucky Consumer Advocate Network swung into action.", "headline": {"main": "States Try to Limit Drugs in Medicaid, But Makers Resist"}, "abstract": "Efforts by states to limit Medicaid payments for some expensive drugs are fought by drug companies that are lobbying heavily and financing consumer group protests; Kentucky's exclusion of Zyprexa, antipsychotic medication that is state's biggest drug expense, was fought by Eli Lilly, which underwrote protests; photo; map and graph showing sharp drop in sales of Zyprexa across country after Kentucky's action; intense lobbying led New York Legislature to override Gov George Pataki's veto and enact law barring Medicare from setting up preferred-drug list, while Oregon Legislature dropped thousands of patients from Medicaid rather than restrict choices for others; drug makers are reluctant to negotiate discounts because federal law requires they then be offered to all states (M)", "print_page": "1", "word_count": 1938, "_id": "4fd27aa48eb7c8105d83f27d", "snippet": "Kentucky's Medicaid program was $230 million in the red last year, and drastic cuts were on the table. A state panel proposed excluding Zyprexa, an antipsychotic medication that is the state's single biggest drug expense, from the Medicaid list of...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/12/18/business/states-try-to-limit-drugs-in-medicaid-but-makers-resist.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "PATAKI, GEORGE E"}, {"name": "glocations", "value": "NEW YORK STATE"}, {"name": "glocations", "value": "KENTUCKY"}, {"name": "glocations", "value": "OREGON"}, {"name": "organizations", "value": "LILLY, ELI, & CO"}, {"name": "subject", "value": "STATES (US)"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "MEDICAID"}, {"name": "subject", "value": "PRICES (FARES, FEES AND RATES)"}, {"name": "subject", "value": "ZYPREXA (DRUG)"}, {"name": "subject", "value": "DISCOUNT SELLING"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "LAW AND LEGISLATION"}, {"name": "subject", "value": "LOBBYING AND LOBBYISTS"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gardiner", "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2003-12-18T00:00:00Z", "section_name": "Front Page; Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "As the AIDS epidemic devastates South Africans, the rising costs of the disease are leading not only to higher insurance premiums and reduced benefits, but also to questions about how best to balance the economic viability of the insurance industry with the government's desire to improve access to financial services and create a bigger private social safety net. In the early days of the epidemic in the United States, many American insurers offered dire predictions about the damage it would do to the insurance system that never came to pass, in large part because infection rates never reached the levels that were feared.", "headline": {"main": "AIDS Costs in South Africa Are Rising"}, "abstract": "Rising costs of AIDS epidemic in South Africa are leading not only to higher insurance premiums and reduced benefits, but also to questions about how best to balance economic viability of insurance industry with government's desire to improve access to financial services and create biger private social safety net; insurance industry is having to adjust to business climate in which 12 percent of total population, and 20 percent of adults, are infected with fatal, transmissible disease at time when profit margins are already shrinking from intensifying competition; photo (M)", "print_page": "1", "word_count": 1227, "_id": "4fd23a198eb7c8105d7ce3c4", "snippet": "As the AIDS epidemic devastates South Africans, the rising costs of the disease are leading not only to higher insurance premiums and reduced benefits, but also to questions about how best to balance the economic viability of the insurance industry...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/12/17/business/aids-costs-in-south-africa-are-rising.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "SOUTH AFRICA"}, {"name": "subject", "value": "ACQUIRED IMMUNE DEFICIENCY SYNDROME"}, {"name": "subject", "value": "HEALTH INSURANCE AND MANAGED CARE"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Nicole", "lastname": "ITANO"}], "original": "By NICOLE ITANO"}, "document_type": "article", "pub_date": "2003-12-17T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "In a 23-to-4 vote, two expert advisory committees to the Food and Drug Administration recommended Tuesday that a so-called morning-after pill to prevent unintended pregnancies be sold over the counter. The F.D.A. usually follows its committees' advice, although the final decision rests with its commissioner, Dr. Mark B. McClellan. But the overwhelming vote by the agency's outside advisers led proponents as well as opponents to expect that Dr. McClellan would go along with the committees, making his decision within weeks to months.", "headline": {"main": "A CONTRACEPTIVE CLEARS A HURDLE TO WIDER ACCESS"}, "abstract": "Food and Drug Administration advisory committees vote overwhelmingly to recommend so-called morning-after pill to prevent unintended pregnancies be sold over the counter; drug, known as Plan B, consists of two high-dose birth control pills; is meant to be used within 72 hours after unprotected sexual intercourse; proponents and opponents expect Comr Mark B McClellan to accept recommendation; photo (M)", "print_page": "1", "word_count": 1286, "_id": "4fd24dbe8eb7c8105d7eea54", "snippet": "In a 23-to-4 vote, two expert advisory committees to the Food and Drug Administration recommended Tuesday that a so-called morning-after pill to prevent unintended pregnancies be sold over the counter.    The F.D.A. usually follows its committees'...", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2003/12/17/us/a-contraceptive-clears-a-hurdle-to-wider-access.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "persons", "value": "MCCLELLAN, MARK B"}, {"name": "organizations", "value": "FOOD AND DRUG ADMINISTRATION"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "PLAN B (CONTRACEPTIVE)"}, {"name": "subject", "value": "BIRTH CONTROL AND FAMILY PLANNING"}], "byline": {"person": [{"organization": "", "role": "reported", "rank": 1, "firstname": "Gina", "lastname": "KOLATA"}], "original": "By GINA KOLATA"}, "document_type": "article", "pub_date": "2003-12-17T00:00:00Z", "section_name": "Front Page; Health; U.S."}], "meta": {"hits": 5, "offset": 0, "time": 33}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}